Canada Markets open in 2 hrs 44 mins

Zymeworks Inc. (ZYME.TO)

Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
33.10+0.53 (+1.63%)
At close: 3:58PM EDT

Zymeworks Inc.

1385 West 8th Avenue
Suite 540
Vancouver, BC V6H 3V9
Canada
604 678 1388
http://www.zymeworks.com

Sector(s)
Industry
Full Time Employees352

Key Executives

NameTitlePayExercisedYear Born
Dr. Ali TehraniCo-Founder, Pres, CEO & Director902.94kN/A1972
Dr. Anthony J. PolverinoChief Scientific Officer & Exec. VP of Early Devel.578.38kN/A1963
Ms. Kathryn O'DriscollChief People Officer108.89kN/A1964
Dr. Diana F. HausmanChief Medical Officer646.51kN/A1963
Dr. Neil Josephson M.D.Sr. VP of Clinical Research564.13kN/AN/A
Mr. Neil A. Klompas C.A., CPA, CPA, CAExec. VP of Bus. Operations & CFON/AN/A1972
Dr. Surjit DixitVP of TechnologyN/AN/A1973
Mr. Daniel DexVP of Legal & Corp. Sec.N/AN/AN/A
Mr. Mark HollywoodSr. VP of Technical & Manufacturing OperationsN/AN/A1969
Dr. Bruce Hart Ph.D.Sr. VP of RegulatoryN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I and Phase II clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and other tumors; and ZW49, a bispecific antibody-drug conjugate that is in Phase I clinical trial for the treatment of advanced or metastatic HER2-expressing cancers. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; collaboration with Applied BioMath, LLC.; and a research collaboration with ImmunoPrecise Antibodies Ltd. for the development of multiple antibody candidates to fight COVID-19. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Corporate Governance

Zymeworks Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.